Pathophysiology News and Research

RSS

Lack of ARHGAP33 molecule causes neuropsychiatric disorders-related abnormal higher brain functions

A research group led by Osaka University and the University of Tokyo found that the intracellular protein trafficking is important for higher brain functions such as learning and memory. The research group showed that a molecule, ARHGAP33 regulates synaptic functions and behaviors via intracellular protein trafficking and that the lack of ARHGAP33 causes neuropsychiatric disorder-related impaired higher brain functions.

29 Mar 2016

Chronic pain patients can reduce emotional response to pain through spinal cord stimulation

Researchers at The Ohio State University Wexner Medical Center have shown that patients who have chronic pain can reduce their emotional response to the pain through spinal cord stimulation.

18 Mar 2016

Study reveals direct regulatory role of serotonin in rheumatoid arthritis

For the first time, serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of rheumatoid arthritis (RA). Although 5-HT is predominantly known as a neurotransmitter within the central nervous system, new evidence points to additional important functions for serotonin in the periphery.

10 Mar 2016

Experts work towards optimizing global diabetes care

Diabetes is a significant global health problem, afflicting 382 million people worldwide with increasing prevalence rates and adverse effects on health, wellbeing, and society in general. In this special issue of the Annals of Global Health, "Global Dimensions of Diabetes Care," experts from around the world synthesize a core set of recommendations using information from 14 countries as a basis in order to work towards optimizing diabetes care globally - a critically important initiative to help stem the diabetes epidemic.

3 Mar 2016

Discovery could lead to better therapies for people with obsessive compulsive disorder

Research led by investigators in veterinary and human medicine has identified genetic pathways that exacerbate severity of canine compulsive disorder in Doberman pinschers, a discovery that could lead to better therapies for obsessive compulsive disorder in people.

27 Feb 2016

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.

26 Feb 2016

Understanding the pathophysiology of bipolar disorder

Advances in magnetic resonance imaging (MRI) acquisition and analyses over the last two decades have enabled the identification of neuroanatomical abnormalities in a range of mental disorders, however one question which has consistently surfaced is the extent to which the medications used to treat such disorders may accentuate or ameliorate these abnormalities.

17 Feb 2016

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Researchers of a new study published in the current issue of Biological Psychiatry report successful reduction of depressive symptoms in patients using a novel non-invasive method of vagus nerve stimulation, or VNS.

5 Feb 2016

Height affects risk of major non-communicable diseases

Height is largely genetically determined, but in recent decades the height of children and adults has steadily increased throughout the world: In adulthood the children are almost always significantly taller than their parents.

3 Feb 2016

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury.

21 Jan 2016

GBI Research says COPD therapeutics pipeline lacks innovation

Analysis from business intelligence provider GBI Research - Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation - states that while currently-available drugs aim to manage the frequency and severity of symptoms associated with COPD, none have been shown to modify long-term disease progression.

19 Jan 2016

Researchers link idiopathic congenital nystagmus to a defect in neurocomputation

Botond Roska and his group at the Friedrich Miescher Institute for Biomedical Research implicate a clearly defined neuron type and its circuit in the retina in the pathophysiology of idiopathic congenital nystagmus.

6 Jan 2016

Concussion expert shares important information on sports-related concussions

The Sports Concussion Program in the Children's Orthopaedic Center at Children's Hospital Los Angeles is the only pediatric program of its kind in Southern California.

26 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

22 Dec 2015

Bile acid may help treat fatty liver disease and obesity

A bile acid that can turn off a receptor in the gut has prevented and reversed fatty liver disease in mice, according to an international team of researchers. The compound may help treat certain metabolic disorders, such as Type 2 diabetes and obesity, as well.

16 Dec 2015

New CRC aims to better understand autophagy at molecular and cellular level

The German Research Foundation (Deutsche Forschungsgemeinschaft/DFG) has approved 11 M € for the next four years for establishing a CRC on selective autophagy under the lead of Goethe University. Autophagy literally means "self-eating" and refers to a sophisticated system in which cellular waste is specifically detected and removed.

12 Dec 2015

Findings may lead to new treatment strategy for phobia

A new study published in the latest issue of Biological Psychiatry reports the successful and instant reduction of fear in spider-fearful participants following a 2-minute exposure combined with a single dose of a regular pharmacological treatment.

11 Dec 2015

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published in the journal Biological Psychiatry suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.

9 Dec 2015

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.